Anthera Pharmaceuticals Inc
OTC:ANTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AdEPT Technology Group PLC
LSE:ADT
|
UK |
|
Echelon Resources Ltd
OTC:NZEOY
|
NZ |
Anthera Pharmaceuticals Inc
Stock-Based Compensation
Anthera Pharmaceuticals Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Anthera Pharmaceuticals Inc
OTC:ANTH
|
Stock-Based Compensation
$6.6m
|
CAGR 3-Years
53%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$955m
|
CAGR 3-Years
12%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
$894m
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
$494m
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$685.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Stock-Based Compensation
$993.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
Anthera Pharmaceuticals Inc
Glance View
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases. The company is headquartered in Hayward, California and currently employs 21 full-time employees. The company went IPO on 2010-03-02. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
See Also
What is Anthera Pharmaceuticals Inc's Stock-Based Compensation?
Stock-Based Compensation
6.6m
USD
Based on the financial report for Mar 31, 2018, Anthera Pharmaceuticals Inc's Stock-Based Compensation amounts to 6.6m USD.
What is Anthera Pharmaceuticals Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
31%
Over the last year, the Stock-Based Compensation growth was -2%. The average annual Stock-Based Compensation growth rates for Anthera Pharmaceuticals Inc have been 53% over the past three years , 31% over the past five years .
